We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




LAMP Accurately Screens for Malaria in Pregnancy

By LabMedica International staff writers
Posted on 23 Jul 2018
Pregnant women are especially susceptible to Plasmodium infections and have the risk of developing severe disease and birth complications. More...
These might include maternal anemia, intra-uterine growth retardation, infant low birth weight, prematurity, miscarriage and stillbirth.

Pregnant women frequently show low-density Plasmodium infections that require more sensitive methods for accurate diagnosis and early treatment of malaria. This is particularly relevant in low-malaria transmission areas, where intermittent preventive treatment is not recommended.

Scientists at the Universidad de Antioquia (Medellín, Colombia) and their international colleagues carried out a nested prospective study that used data and samples from a larger cross-sectional project conducted from May 2016 to January 2017 in three Colombian endemic areas. A total of 531 peripheral and placental samples were collected from pregnant women self-presenting at local hospitals for antenatal care visits, at delivery or seeking medical care for suspected malaria.

Blood samples were analyzed for Plasmodium parasites by light microscopy (LM), rapid diagnostic test (RDT) and loop mediated isothermal amplification (LAMP). The team used RDT SD Bioline Malaria antigen Pf/Pv as it can distinguish between P. falciparum, P. vivax and mixed infections. The commercially available Loopamp MALARIA Pan/Pf detection kit consists of reaction tubes with ready-made vacuum-dried reagents for the detection of P. falciparum (Pf-LAMP) or Plasmodium spp. (Pan-LAMP). DNA was extracted from half blood-spot filters and processed for a universal polymerase chain reaction (PCR) followed by nested species-specific PCR (nPCR) to detect the 18S ribosomal gene of P. falciparum, P. vivax and P. malariae.

The team reported that in peripheral samples, LAMP showed an improved sensitivity of 100% when compared with LM 79.5% and RDT 76.9%, particularly in afebrile women, for which LAMP sensitivity was, two-times higher than LM and RDT. Overall agreement among LAMP and nPCR was high. In placental blood, LAMP evidenced a four-fold improvement in sensitivity (88.9%) when compared with LM and RDT (22.2%), being the only method, together with nPCR, able to detect placental infections in peripheral blood.

The authors concluded that LAMP is a simple, rapid and accurate molecular tool for detecting gestational and placental malaria, being able to overcome the limited sensitivity of LM and RDT. These findings could guide maternal health programs in low-transmission settings to integrate LAMP in their surveillance systems for the active detection of low-density infections and asymptomatic malaria cases. The study was published on July 13, 2018, in the Malaria Journal.

Related Links:
Universidad de Antioquia


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.